Sanofi licenses autoimmune asset from Nurix; Sumitomo Pharma’s changes

Plus, news about Gilead, Roche, Desentum, Inhibrx and Pila Pharma: After 2020 deal, Sanofi licenses Nurix’s autoimmune disease asset: The discovery-stage program targets a “previously undruggable” transcription factor that regulates inflammatory ...

Related Posts

Novo's weight loss drug helps curb some drinking habits...

Feb 12, 2025  0

Praxis' essential tremor drug fails interim Phase 3 rea...

Feb 28, 2025  0

New pharma tariffs could put generic drugmakers under p...

Mar 27, 2025  0

Comments

Name

Email

Comment

Post Comment